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Summary
Erythropoietic protoporphyria (EPP; MIM 177000) is
an inherited disorder caused by partial deficiency of fer-
rochelatase (FECH), the last enzyme in the heme bio-
synthetic pathway. In EPP patients, the FECH deficiency
causes accumulation of free protoporphyrin in the ery-
thron, associated with a painful skin photosensitivity. In
rare cases, the massive accumulation of protoporphyrin
in hepatocytes may lead to a rapidly progressive liver
failure. The mode of inheritance in EPP is complex and
can be either autosomal dominant with low clinical pen-
etrance, as it is in most cases, or autosomal recessive.
To acquire an in-depth knowledge of the genetic basis
of EPP, we conducted a systematic mutation analysis of
the FECH gene, following a procedure that combines
the exon-by-exon denaturing-gradient-gel-electropho-
resis screening of the FECH genomic DNA and direct
sequencing. Twenty different mutations, 15 of which are
newly described here, have been characterized in 26 of
29 EPP patients of Swiss and French origin. All the EPP
patients, including those with liver complications, were
heterozygous for the mutations identified in the FECH
gene. The deleterious effect of all missense mutations
has been assessed by bacterial expression of the respec-
tive FECH cDNAs generated by site-directed mutage-
nesis. Mutations leading to a null allele were a common
feature among three EPP pedigrees with liver compli-
cations. Our systematic molecular study has resulted in
a significant enlargement of the mutation repertoire in
the FECH gene and has shed new light on the hereditary
behavior of EPP.
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Introduction
Erythropoietic protoporphyria (EPP; MIM 177000) is
an inherited disorder of heme biosynthesis, first recog-
nized by Magnus et al. (1961). EPP is caused by a partial
deficiency of ferrochelatase (FECH; E.C.4.99.1.1), the
terminal enzyme of the heme biosynthetic pathway that
catalyzes the insertion of ferrous iron into protopor-
phyrin IX to form heme. In EPP patients, the accumu-
lation of free protoporphyrin because of FECH defi-
ciency takes place principally in the erythropoietic tissue.
Clinically, an excess amount of free protoporphyrin ac-
cumulates in the skin, causing an extremely painful pho-
tosensitivity in patients, starting at early childhood. In
!5% of patients, the accumulation of protoporphyrin in
the liver leads to liver injury characterized by cholestasis
and unpredictable terminal liver failure (Kappas et al.
1995).
The cDNA sequence of 423 amino acid residues that
encodes human FECH has been published (Nakahashi
et al. 1990 [GenBank D00726]), together with the struc-
ture and location of the FECH gene on chromosome
18q21.3 (Whitcombe et al. 1991; Taketani et al. 1992).
The FECH gene contains 11 exons and spans ∼45 kb.
To date, 23 different molecular defects in the FECH gene
have been described, coming from a number of reports
mostly based on FECH cDNA analysis (for references,
see table 1). However, no molecular-analysis strategy has
yet been developed for examining the FECH gene mu-
tations systematically.
The mode of inheritance of EPP is mainly autosomal
dominant with incomplete penetrance but, rarely, can
be autosomal recessive (Lamoril et al. 1991; Cox 1997).
In the dominant type of EPP, different degrees of enzyme
deficiency can be seen in patients versus asymptomatic
gene carriers—that is, symptomatic patients usually have
!50% of the normal activity, whereas asymptomatic
gene carriers show ∼50% of normal activity (Bon-
kowsky et al. 1975; Deybach et al. 1986; Norris et al.
1991). This indicates that factors in addition to the mu-
tations are involved in the phenotypic manifestations of
EPP. In one family, “low expression” of an apparently
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Table 1
Mutations in the Human FECH Gene
Exon and Mutation Sequence Modificationa Relationship to Liver Diseaseb Reference(s)
1:
del G40 Frameshift Todd et al. (1993)
2:
G163rT G55C Lamoril et al. (1991)
C175rT Q59X Present/absent Schneider-Yin et al. (1994a)/present study
3:
IVS32, trg SD (del exon 3) Sarkany et al. (1994b)
T212rA I71K Present study
ins T213 Frameshift Present in P5, absent in P6 Present study
C286rT Q96X Henriksson et al. (1996)
4:
C343rT R115X Absent/present Henriksson et al. (1996)/present study
T451rC S151P Present study
G463C SD (del exon 4) Wang (1996)
IVS41, grc SD (del exon 4) Present study
5:
T557rC I186T Imoto et al. (1996)
T571rC Y191H Present study
C574rA P192T Present study
del TACAG580 Frameshift Schneider-Yin et al. (1995); present study
7:
IVS71, gra SD (del exon 7) Nakahashi et al. (1993a)
IVS75, gra SD (del exon 7) Wang et al. (1994)
del T709 Frameshift Present Present study
del GAGGA751 Frameshift Henriksson et al. (1996)
G801rA M267I Lamoril et al. (1991)
8:
C848rT T283I Present study
T863rA M288K present study
del TG899 Frameshift Schneider-Yin et al. (1994a); present study
G903rA W301X Present study
IVS81, grt SD (del exon 8) Wang et al. (1995)
9:
IVS82, arg SA (del exon 9) Present study
IVS91, gra SD (del exon 9) Present Nakahashi et al. (1993b)
10:
IVS92, arg SA (del exon 10) Present study
IVS101, grt SD (del exon 10) Present study
IVS101, del g SD (del exon 10) Gouya et al. (1996)
IVS103, arg SD (del exon 10) Present Sarkany et al. (1994a)
C1001rT P334L Present study
T1088rG SD (del exon 10) Present Sarkany et al. (1994a)
del T1122 Frameshift Henriksson et al. (1996)
A1135rT K379X Wang et al. (1993); present study
11:
T1250rC F417S Brenner et al. (1992)
del CTT1248 del F417 Present study
Complete deletion of one FECH allele (del 18q) Magness et al. (1994)
a SD  splice donor–site mutation; and SA  splice acceptor–site mutation.
b A virgule (/) indicates that the mutation has been given two, different classifications, which correspond, respectively, to the two studies
shown in the “References” column.
normal FECH allele in combination with a mutant allele
has been proposed as being responsible for the EPP phe-
notype (Gouya et al. 1996). Whether this phenomenon
is generally operative and would explain the puzzling
aspects of dominant EPP remains to be confirmed.
There is currently no known index that predicts the
onset or severity of the disease. A systematic analysis of
the FECH gene mutations is a prerequisite for investi-
gating the inheritance patterns of EPP, for seeking ge-
notype-phenotype relationships, and for providing fur-
ther insight into the genetic mechanisms responsible for
decreased FECH activity in EPP. In this study, we de-
veloped a two-step screening strategy using denaturing
gradient gel electrophoresis (DGGE) followed by direct
sequencing, in order to rapidly identify FECH gene mu-
tations in all 11 exons plus intron/exon boundaries. This
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strategy was applied to a large Swiss and French EPP
cohort and identified a number of novel mutations in
this gene.
Subjects and Methods
Patients and Specimens
Twenty-nine unrelated EPP patients of French and
Swiss origin were studied. The diagnosis of EPP was
established unequivocally, on the basis of the clinical
symptoms of photosensitivity, increased protoporphyrin
concentrations in red blood cells (RBCs) and feces, and/
or partial reduction of FECH activity (table 2). Periph-
eral blood samples were collected from the patients and
their family members, with informed consent. Lympho-
cyte FECH activity was measured fluorometrically on
the basis of zinc-mesoporphyrin formation, according to
the method described by Li et al. (1987). FECH mea-
sured in most of the patients show an average residual
activity that was 32% of the normal level (the mean 
2 SD was 1.6 0.5 in patients vs. 5.0 1.5 in controls),
a level characteristic of symptomatic EPP patients. Two
patients (P7 and P15) underwent liver transplantation
before the study, and a third patient (P5) had a brother
who died of liver failure. The main clinical and bio-
chemical data of EPP patients are summarized in
table 2.
In Vitro Amplification of Genomic DNA
Genomic DNA was isolated by use of either a pro-
cedure described by Loparev et al. (1991) or a QIAamp
Blood kit (QIAGEN). Each of the 11 exons of the FECH
gene was amplified by PCR using primer sets listed in
the Appendix (table A1). The PCR fragments cover the
respective exons and their flanking intronic sequences
(two overlapping fragments, in the case of exons 4 and
11). PCR conditions were as follows: a 30-ml reaction
mixture containing 0.2–1 mg of genomic DNA, 100 pmol
of each primer, 10 mM Tris-HCl, pH 8.3, 50 mM KCl,
1.5 mM MgCl2, and 200 mM of each dNTP was incu-
bated at 94C for 5 min. Then, 20 ml of a second reaction
mixture was added (“hot start”), containing 10 mM
Tris-HCl, pH 8.3, 1.5 mM MgCl2, and 3.5 U of High-
Fidelity Taq polymerase (Boehringer Mannheim). The
reactions were performed in 40 amplification cycles,
each of 1 min at 94C, 1 min at the annealing temper-
atures given in the Appendix (table A1), and 1 min of
elongation at 72C.
Reverse-Transcription PCR (RT-PCR)
Total RNA was extracted from isolated peripheral
blood mononuclear cells by means of a standard tech-
nique (Chomczynski and Sacchi 1987). cDNA was ob-
tained by reverse transcription of total RNA, with
oligo(dT) used as a primer. FECH cDNA was amplified
as described elsewhere (Gouya et al. 1996).
DGGE Analysis of the FECH Gene
Aliquots (30 ml) of the amplified fragments were an-
alyzed by DGGE in a D GENE System (BioRad-Her-
cules). Two electrophoretic parameters—namely, the de-
naturant concentration (100% denaturant corresponds
to 7 M urea and 40% deionized formamide) and the
running time—were selected for the individual fragment
by computer analyses using Melt 87 and SQHTX soft-
ware (Lerman and Silverstein 1987). Linear gradients of
the denaturant were formed in 7.5% polyacrylamide gels
(acrylamide:bisacrylamide ratio 37.5:1) with a size of
cm. Electrophoreses were performed at a con-16# 16
stant 120 V in TEA buffer (40 mM Tris acetate, 20 mM
sodium acetate, and 1 mM EDTA, pH 7.4). The DNA
fragments were photographed under a UV transillumi-
nator after ethidium bromide staining. For each EPP
patient, all 11 exons and their intron-flanking sequences
were systematically analyzed by DGGE, to eliminate the
possibility of another sequence variation and to ensure
that the detected base substitution could not be due to
a polymorphism. However, since DGGE patterns of
exon 1 were not always conclusive, exon 1 was se-
quenced in all EPP patients. DGGE conditions for the
FECH exons were optimized by running the samples
with already well-characterized mutations in the respec-
tive sequences (including known polymorphisms). One
to three of the so-called positive controls were used for
each exon–mobility-shift assay, and some of these con-
trol DGGE profiles are presented in figure 1.
Sequencing of Genomic DNA
DNA fragments with abnormal DGGE patterns were
directly sequenced by use of the fMol DNA sequencing
kit (Promega-Biotech) with 35S-dATP and primers listed
in the Appendix (table A2).
Construction and Prokaryotic Expression of Normal
and Mutated Human FECH cDNA
The normal human FECH cDNA was expressed by
means of the pGEX-2T expression vector (Pharmacia
LKB Biotechnology), according to a procedure described
by Lamoril et al. (1995). To study missense mutations
and deletions, site-directed mutagenesis was performed,
with the normal cloned FECH cDNA (pGEX-FECH)
used as template. We used the transformed site-directed
mutagenesis kit (Clontech Laboratories) based on
the long-primer unique site–elimination mutagenesis
method described by Deng and Nickoloff (1992). In
brief, long primers were generated by PCR. The 5′-phos-
phorylated sense oligonucleotide (mutagenic primer) in-
troduced the mutation. A 5′-phosphorylated antisense
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Table 2
Clinical and Biochemical Data and Mutations Identified in the FECH Gene of EPP Patients
PATIENT
(ORIGIN)
AGE
(SEX)
CLINICAL
SYMPTOM(S)a
PROTOPOR-
PHYRIN IN
RBCSb
(mM/liter)
FECH ACTIV-
ITY IN LYM-
PHOCYTES AT
37Cc
(nmol zinc-me-
soporphyrin/h/
mg protein)
EXON
AFFECTEDd
FECH GENE MUTATION
SEQUENCE
MODIFICATIONfNovel Knowne
P1 (Swiss) 32 (M) PS 40.6 ) 2 C175rT Q59X
P2 (Swiss) 41 (F) PS 38.5 ) 2 C175rT Q59X
P3 (Swiss) 38 (F) PS 11.7 ) 2 C175rT Q59X
P4 (Swiss) 41 (F) PS 44.3 ) 3 T212rA I71K
P5 (Swiss) 32 (M) PS, ALF 88.0 ) 3 ins T213 Frameshift
P6 (Swiss) 7 (F) PS 46.0 ) 3 ins T213 Frameshift
P7 (French) 49 (F) PS, LT 25.6 1.5 4 C343rT R115X
P8 (Swiss) 15 (F) PS 13.2 ) 4 T451rC S151P
P9 (French) 51 (M) PS 29.5 1.6 4 IVS41, grc SD (del exon 4)
P10 (French) 13 (M) PS 4.0 2.5 5 T571rC Y191H
9 IVS82, arg SA (del exon 9)
P11 (French) 65 (F) PS, PG 17.8 1.8 5 C574rA P192T
P12 (Swiss) 44 (F) PS 14.6 ) 5 del TACAG580 Frameshift
P13 (Swiss) 42 (F) PS 17.6 ) 5 del TACAG580 Frameshift
P14 (French) 20 (M) PS 23.4 1.3 5 del TACAG580 Frameshift
P15 (French) 35 (F) PS, LT 97.0/28.6g .8 7 del T709 Frameshift
P16 (French) 19 (M) PS 41.6 1.8 8 C848rT T283I
P17 (French) 59 (M) PS 7.8 1.6 8 T863rA M288K
P18 (Swiss) 18 (M) PS, ALF 26.0 ) 8 del TG899 Frameshift
P19 (Swiss) 31 (M) PS 12.5 ) 8 del TG899 Frameshift
P20 (Swiss) 8 (M) PS 23.5 ) 8 del TG899 Frameshift
P21 (French) 54 (F) PS, PG 10.8 1.1 8 G903rA W301X
P22 (French) 15 (F) PS 3.4 2.2 10 IVS92, arg SA (del exon 10)
P23 (French) 23 (M) PS 26.4 1.1 10 IVS101, arg SD (del exon 10)
P24 (French) 24 (M) PS 22.3 1.4 10 C1001rT P334L
P25 (French) 51 (F) PS 43.4 1.2 10 A1135rT K379X
P26 (French) 16 (F) PS 19.9 1.6 11 del CTT1248 del F417
P27 (French) 6 (F) PS 13.2 1.0 ND ) ) )
P28 (French) 25 (M) PS 24.4 2.4 ND ) ) )
P29 (Swiss) 34 (M) PS 19.9 ) ND ) ) )
a PS  photosensitivity of the skin; ALF  abnormal liver function, evaluated in serum by standard clinical chemistry tests (transaminases,
alkaline phosphatase, and gamma glutamyl transpeptidase); LT  liver transplantation; and PG  protoporphyrin gallstone.
b Normal !1.9.
c Normal (mean  SD)  5.0  1.5. An ellipsis ()) denotes that data were not available.
d ND  not detected.
e For references, see table 1.
f SD  splice donor–site mutation; and SA  splice acceptor–site mutation.
g Before/after liver transplantation.
oligonucleotide, which mutates a unique BsaAI restric-
tion site in the pGEX-FECH plasmid (selection primer),
was used. The sequences of these primers are given in
the Appendix (table A3). Standard DNA elongation, li-
gation, and two-step digestion/transformation of mu-
tated plasmids in mutS Escherichia coli and E. coli
DH5a strains were performed according to the supplier’s
recommendations. The entire sequence of the mutated
plasmid was verified by sequencing.
FECH Activity in Crude Bacterial Extracts
The recombinant bacteria (E. coliDH5a) were grown,
and FECH activity in bacteria lysates was determined,
by the same procedure as was used for measurement of
lymphocyte FECH activity (see Patients and Specimens
subsection).
Results
Fifteen Novel mutations in the FECH Gene
A total of 20 different mutations, including 15 “new”
mutations (i.e., not described in previous studies), have
been identified in the FECH gene of 26 of 29 EPP pa-
tients studied. DGGE gels from 10 exonic fragments
with different mobility shifts are shown in figure 1. The
subsequent sequencing of the samples with an abnormal
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Figure 1 DGGE analysis of nine exons of the FECH gene. Lane N, Normal controls (i.e., samples with absence of either heterozygosity
for mutations or polymorphisms, which appeared as a single band on the DGGE gels). Lanes P1–P26, Samples from different EPP patients
with abnormal DGGE patterns (i.e., double, triple, or quadruple bands with different migration rates). The descriptions of the mutations,
revealed by subsequent direct sequencing, are given in table 2. Lanes pm1–pm3, Three polymorphisms—287A/G, 798G/C, and 921A/G, respectively.
Patterns from four of the positive control samples (samples with already known mutations) used in the study are presented: C1, del AA168; C2,
T790C; C3, del AG970; and C4, IVS101, del g.
DGGE pattern revealed the causative mutation (table 2).
Eight of the 15 new mutations are point mutations that
lead to substitution of a single amino acid in the FECH
protein. Four additional point mutations lie inside in-
tronic sequences, predicting anomalous RNA splicings
of exons 4, 9, and 10. In these cases, the skipping of the
respective exons was verified by RT-PCR and cDNA
electrophoresis (figs. 2 and 3C). A 1-bp insertion, ins
T213, and a 1-bp deletion, del T709, causing frameshifts
with stop signals occurring, respectively, 9 and 6 codons
downstream, may result in formation of a truncated pro-
tein. A 3-bp deletion, del CTT1248, removes a phenyl-
alanine residue at position 417 (DF417), near the car-
boxyl-terminus of FECH. No mutations were found in
three patients (P27, P28, and P29), either by DGGE
screening or by further sequencing of the 11 exons and
the respective exon/intron boundaries. Patient P27 was
shown to have only one FECH allele expressed, on the
basis of haplotyping and polymorphism study. In this
patient, the heterozygosity with respect to the FECH
gene polymorphisms in the genomic DNA was absent
in cDNA, and, as expected, the steady-state mRNA level
was half of normal. Sequencing of the promoter region
(500 bp upstream from the initial codon) failed to detect
any abnormalities. In the two remaining patients (P28
and P29) from whom only genomic DNA was available,
DGGE screening and sequencing of the corresponding
DNA fragments were unable to identify any sequence
variations. Study of seven known intragenic polymor-
phic sites (251a/g, IVS123c/t, IVS2 dinucleotide repeat,
287A/G, 798G/C, 921A/G, and 1520C/T) spreading over the
FECH gene, from the promotor to the 3′ UTR, indicated
that both FECH alleles were present and that the FECH
locus was largely intact in both patients.
During this study, three known exonic polymor-
phisms—287A/G, 798G/C, and 921A/G—have been dis-
cerned in DGGE gels of exons 3, 7, and 9, respectively
(fig. 1). The allelic frequencies of these three polymor-
phic sites, as determined by their specific DGGE patterns
in samples from 50 normal subjects, were 9% versus
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Figure 2 Agarose gel electrophoresis (ethidium bromide stain-
ing) of RT-PCR products from patients with splicing defects: exon 4
in patient P9 and exon 10 in patients P22 and P23. The sizes of PCR
products are indicated. The size differences between normal cDNA
fragments (upper bands) and cDNA fragments lacking the respective
exon are 149 bp (exon 4 skipping) and 60 bp (exon 10 skipping).
Lanes N, Normal control. Lane M, Molecular-weight markers.
Figure 3 Genomic and cDNA analyses of EPP family P10 . A,
Exon 5 DGGE profile of FECH genomic DNA (mutation Y191H). B,
Exon 9 DGGE profile of FECH genomic DNA (IVS82, arg). C, Aga-
rose gel electrophoresis of normal FECH cDNA fragment (599 bp)
and exon 9–skipped fragment (434 bp). Lane N, Normal control. Lane
MW, Molecular-weight markers.
91%, for 287A/G; 70% versus 30%, for 798G/C; and 72%
versus 28%, for 921G/A. Allelic frequencies of these pol-
ymorphisms in our EPP cohort were similar to those of
the normal subjects.
Recurrent Mutations among Swiss EPP Patients
A relatively high incidence of recurrent mutations was
observed among the Swiss EPP patients. The family his-
tory of each Swiss EPP case was recorded, to x3 gen-
erations prior to the index patient. None of the Swiss
families included in this study appeared to be related,
on the basis of the data that were available. Table 3 lists
four mutations that were identified in at least two un-
related Swiss patients; three of these mutations had been
published previously, and one is new. The number of
Swiss EPP patients having one of these four mutations
constituted 86% (12/14) of the total Swiss EPP cases
studied so far. Mutations del TACAG580 and del TG899
were also found in patients P14 and P18, from France.
In Vitro Expression of Mutated FECH Genes
To examine the impact of the mutations on FECH
activity, seven new point mutations (I71K, S151P,
Y191H, P192T, T283I, M288K, and P334L), as well as
the 3-bp in-frame deletion CTT1248–1250, were expressed
in a bacterial system. The nonsense mutation G903rA,
leading to substitution of tryptophan-301 by a stop co-
don, is likely to generate an inactive enzyme and, there-
fore, was not expressed. All expression constructs except
pGEX-Y191H showed dramatic reduction in FECH ac-
tivity—that is, !19% that of the normal enzyme (table
4). As shown in the sequence alignment of six different
FECHs (fig. 4), all substitutions occurred at amino acid
residues that are highly conserved, at least among mam-
malian species. The T571rC transition that led to the
Y191H substitution (which retains 72% of normal ac-
tivity) was found to be associated with a second mu-
tation (a splice-site disruption, IVS82, arg; see below),
located on the same FECH allele, and is likely to com-
pletely inactivate the enzyme.
Two Mutations on the Same Allele of the FECH Gene
Twenty-five of the 26 positively identified EPP patients
were simple heterozygotes for their respective mutations.
The exception was patient P10. In this patient, DGGE
screening and the subsequent sequencing unveiled two
distinct mutations (Y191H and IVS82, arg; table 2) in
the FECH gene. By DGGE screening of exons 5 and 9,
these two mutations were identified in the patient’s
mother but not in his father, suggesting that, in this
particular EPP family, the two mutations reside on the
same allele of the FECH gene (fig. 3A and B). The pres-
ence of an anomalous cDNA species lacking exon 9, as
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Table 3
Recurrent Mutations among Swiss EPPs
Exon Patients Mutation Frequency
2 RSa, P1, P2, P3, C175rT 4/14
3 P5, P6 ins T213 2/14
5 DVb, P12, P13 del TACAG580 3/14
8 MBa, P19, P20 del TG899 3/14
a Source: Schneider-Yin et al. (1994a).
b Source: Schneider-Yin et al. (1995).
Table 4
Expression of Mutated FECH in E. coli
Patient Construct
Specific Activity of
FECH at 37Ca
(nmol zinc-mesopor-
phyrin/h/mg lysate
protein)
Residual Activity of
Human FECHb
(%)
pGEX .0 .0
pGEX-FECH 16.0 100.0
P4 pGEX-I71K .1 !.5
P8 pGEX-S151P .1 !.5
P10 pGEX-Y191H 11.3 72.0
P11 pGEX-P192T .1 !.5
P16 pGEX-T283I .45 2.8
P17 pGEX-M288K .1 !.5
P24 pGEX-P334L 3.0 19.0
P26 pGEX-del CTT1248 .1 !.5
a Mean of four experiments.
b As calculated from the reference value of the normal human FECH cDNA construct
(pGEX-FECH).
a result of the IVS82, arg mutation, was confirmed in
both the patient and his mother, by RT-PCR and cDNA
electrophoresis (fig. 3C).
Family Studies of EPP Patients with Liver
Complications
Patients P7 and P15 suffered from severe liver com-
plications and underwent liver transplantation, which
corrected cholestasis and normalized the liver-function
tests. The erythrocyte protoporphyrin has remained !30
mM/liter, for 4 years in patient P7 and for 2 years in
patient P15, after the liver transplantations. A third pa-
tient, P5, whose brother died of EPP-related liver disease,
displayed abnormal liver-function tests. Three different
mutations—a single base insertion (ins T213, in patient
P5), a single base deletion (del T709, in patient P15), and
a nonsense mutation (R115X, in patient P7)—were iden-
tified in the FECH genes of these three patients (table
2). No other mutations were found in the FECH DNA
sequences. The transmission of these single mutations
within the affected pedigrees (fig. 5) was followed by
DGGE screening.
Discussion
We have conducted the first systematic mutation study
of 29 EPP patients, using a strategy combining a DGGE
screening method with targeted sequencing—namely, a
sequencing of only those exons or DNA fragments that
have abnormal DGGE patterns. In most of the previ-
ously published EPP cases, mutation detection was per-
formed by molecular analysis of the FECH cDNA (1.3
kb). DGGE as a screening method has been shown to
be highly sensitive in the mutation study of the por-
phobilinogen deaminase gene in acute intermittent por-
phyria (Puy et al. 1997; MIM 176000). In our study,
DGGE screening of EPP patients has achieved an overall
detection rate of 90% (26/29 patients). The undetected
abnormalities in three EPP cases may involve mutations
in unexplored parts of the gene, as has been reported
for other porphyrias (Puy et al. 1997). However, the size
(45 kb) of the FECH gene precludes the use of a complete
analysis of gene defects as a routine analysis in EPP
patients.
Our finding of 15 new mutations expands to 38 the
list of all known mutations in the FECH gene (table 1).
In general, mutations in the FECH gene are highly het-
erogeneous and often are family specific, as is the case
among the French EPP patients whom we studied. Cer-
tain prevalent mutations, however, were observed
among the Swiss EPP patients whom we studied. The
“recurrent” mutations probably reflect, to a certain ex-
tent, the genetic make-up of the relatively isolated Swiss
population.
As shown in table 1, the FECH gene mutations are
spread over 10 exons. So far, no mutations have been
found in exon 6. Although no “hot spots” for mutation
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Figure 4 Comparison of amino acid sequences deduced from nucleotide sequences of human (HS), mouse (MM), bovine (Bo), Sacchar-
omyces cerevisiae (Sc), E. coli (Ec), and Bacillus subtilis (Bs). Periods (.) indicate amino acids that are identical in all FECHs; and asterisks (*)
indicate amino acids that are identical in mammalian FECHs. The numbers and the boxes indicate the position of the amino acids substituted
in the human sequence.
Figure 5 Pedigree of three EPP families with severe liver disease.
A nonsense mutation (C343rT) and frameshift mutations (ins T213 and
del T709) were identified in P7, P5, and P15, respectively. Among in-
dividuals who carry the mutation, overt and asymptomatic EPP pa-
tients are indicated by completely blackened and half-blackened sym-
bols, respectively. Unblackened symbols denote normal individuals.
The unblackened circle containing a question mark denotes an indi-
vidual who was not tested. The clinical conditions of the EPP patients
is indicated in paraphrases: photosensitivity (a), liver failure (b), liver
transplantation (c), and abnormal liver-function tests (d).
can be clearly localized on the basis of the currently
available data, exon 10 of the FECH gene seems to be
a more frequent target for mutations than are other ex-
ons. The predominant type of mutations are single-nu-
cleotide substitutions in the coding region of the FECH
gene (42%), followed by exon skippings (34%) and
small deletions and insertions (21%). For the first time,
a base-pair insertion (ins T213) has been found in the
FECH gene. A complete deletion of one FECH allele,
due to loss of chromosome 18q, has been reported, so
far, in one patient (Magness et al. 1994).
In earlier publications on mutation analyses in the
FECH gene, exon skipping was the dominant type of
mutation in the spectrum. That might reflect certain bias
due to the fact that deletions of large fragments of RNA,
as results of the exon skippings, were easily recognizable
and therefore selectively captured when cDNAs were
analyzed. DGGE screening of the genomic DNA, on the
other hand, detects mutations indiscriminately.
So far, limited data are available on the structural
features and catalytic mechanism of human FECH, be-
cause its tertiary structure is not yet resolved. Mutation
analysis provides important information for study of the
function of individual amino acids in the overall catalytic
process. F417, located 6 amino acid residues away from
the C-terminus, has been extensively studied. The first
naturally occurring mutation found to affect F417 was
the T1250rC transition, converting phenylalanine-417 to
serine (F417S; Brenner et al. 1992). In vitro expression
of mutant F417S showed !2% of normal activity. To
further examine the role of F417, a number of other
mutants—F417L, F417Y, and F417W—were con-
structed, by means of site-directed mutagenesis (Dailey
et al. 1994). All showed little or no measurable enzyme
activity. Combining the experimental results from the
human FECH, as well as from yeast and bacterial
FECHs, Dailey et al. (1994) proposed that F417 is di-
rectly involved in maintaining the enzyme stability. Our
patient P26 presented a new genotype—namely, the
F417 deletion in the protein. The mutant FECH devoid
of F417 was totally inactive when expressed in vitro,
confirming F417’s importance for complete enzyme
activity.
The inheritance of EPP is rather complex. The FECH
mutations in the majority of EPP patients are transmitted
as an autosomal dominant trait, however, with incom-
plete penetrance and variable clinical expression. There
have been two confirmed cases shown to be compound
heterozygotes for distinct mutations identified on both
alleles of the FECH gene (Lamoril et al. 1991; Sarkany
et al. 1994a). Recessive inheritance was demonstrated
by coinheritance of the two disabling alleles from asymp-
tomatic parents. In our study, we found only one FECH
mutation in genomic DNA from each of the 25 patients,
suggesting that compound heterozygosity is a rare event
in EPP. In the EPP families that we examined, all mu-
tations were transmitted as an autosomal dominant trait.
Two mutations identified in patient P10, however,
aligned on the same allele of the FECH gene. The two
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mutations were clearly not equally deleterious to the
enzyme: whereas exon 9 skipping (as the result of the
point mutation in the acceptor site of intron 8) inacti-
vated the enzyme, the Y191H substitution (as the result
of T571rC transition) caused only a slight reduction of
the enzyme activity (72% of normal) when it was ex-
pressed in a bacterial system. The expression results,
together with the fact that the Y191H mutation has
never been reported in EPP, suggest that this mutation
may play either a minor or no role in FECH deficiency
and might be a rare polymorphism.
Liver failure is a rare, albeit life-threatening, compli-
cation of EPP. There have been three published cases on
the genetic analysis of EPP with liver complications (Na-
kahashi et al. 1993a; Sarkany et al. 1994a; Schneider-
Yin et al. 1994a, 1994b). We report here three new
cases—P5, P7, and P15. Although the total number of
studied cases is still small, EPP patients with liver com-
plications do exhibit certain unique features that differ-
entiate them from EPP patients having only symptoms
of photosensitivity: (1) In the three EPP pedigrees re-
ported here, there is an unusual high clinical penetrance
of the disease, with at least two symptomatic EPP pa-
tients (with or without liver complications) in one gen-
eration (fig. 5). (2) So far, all known molecular defects
in EPP patients with liver complications are either frame-
shifts or nonsense mutations. In the six studied EPP cases
(table 1), no missense mutation was found to be asso-
ciated with liver complications. In other words, EPP pa-
tients with nonsense mutations, deletions, insertions,
and exon skipping might be at higher risk of developing
liver disease than are EPP patients with missense mu-
tations. (3) In most of these cases, a single mutation is
the sole abnormality in the FECH gene. Only one con-
firmed EPP case with liver complications involved two
mutations on both alleles of the gene (Sarkany et al.
1994a).
Incomplete penetrance and variable clinical symp-
toms, ranging from mild photosensitivity to severe liver
injury, are the puzzling features of EPP. Although our
present knowledge cannot provide definitive answers to
questions concerning the etiology of EPP, there is a
strong indication that multiple factors play a collective
role in the outcome of the disease. The FECH gene mu-
tations leading to partial deficiency of FECH activity are
certainly the primary cause of the EPP condition. A low
expression of the normal FECH allele has been shown
to account for the inheritance of protoporphyria in one
pedigree, which might explain the lower than expected,
50% FECH residual activity in this EPP patient (Gouya
et al. 1996). However, in all protoporphyric patients
reported here, there is no strict correlation between ge-
netic defects and either the erythrocyte protoporphyrin
levels, the residual FECH activities, or the disease se-
verity (table 2). So far, neither heterozygosity nor ho-
mozygosity (compound heterozygosity) for FECH gene
mutations has been shown to be directly associated with
distinct clinical presentations—that is, photosensitivity
versus liver complication. Finally, genetic background of
individuals is strongly suggested to contribute to the var-
iable disease expression. This hypothesis is supported by
the various clinical manifestations, ranging from mild
skin photosensitivity to terminal liver failure, among the
four unrelated Swiss patients (patients RS, P1, P2, and
P3) who carry the same point mutation, C175rT, Q59X
(table 3). In these four patients, the C175rT transition is
the only mutation identified in the FECH gene, indicat-
ing that other genetic and/or environmental factors may
affect the severity of EPP. A similar phenomenon has
also been observed in a mouse EPP model. The same
mutation, Fechm1Pas (T293rA, M98K), in the homozygous
state led to a severe phenotype with rapid liver injury
(cytolysis and cholestasis) in the BALB/c strain (Tutois
et al. 1991; Boulechfar et al. 1993) but led to a much
milder clinical presentation (absence of cytolysis and
mild cholestasis) when expressed in the C57BL/6 strain
(J. C. Deybach, unpublished data).
Undoubtedly, a systematic analysis of the molecular
defects in the FECH gene among EPP patients and their
family members is the initial and important step toward
understanding of the inheritance and pathophysiology
of EPP, a step that is the basis for a proper genetic coun-
seling. Our study has shown that a DGGE-based strategy
is suitable as a way to perform, with high efficiency and
sensitivity, mutation analysis in the FECH gene.
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Appendix
Table A1
PCR Primers and Conditions for DGGE Analysis of FECH Exons
EXON
PRIMER SEQUENCEa
ANNEALING
TEMPERATURE
(C)
DENATURANT
(%)
RUNNING
TIME
(h)Forward Reverse
1 5′-CACTGCTGGGCGGACACCTG-3′ 5′-ggacagacccacttacGCGG-3′ 57 59–99 8
2 5′-gatttcatgcgagcacttta-3′ 5′-tcttatttgtacctgatgtt-3′ 53 38–78 6
3 5′-aaccgttgtattttatttta-3′ 5′-tgtcaatgtagtgccaaggt-3′ 53 15–59 6
4a 5′-aatccacttacctgtatgtt-3′ 5′-TTGGAAGTCCATATCTTGAT-3′ 52 34–74 6
4b 5′-GATTCAAGAGCAGTACCGCA-3′ 5′-ttcgaaagaactaatctaat-3′ 53 31–71 4
5 5′-tccacatgtctcttcctaat-3′ 5′-cgtatctaacctttccactg-3′ 50 28–68 8
6 5′-gcatctactaagtggtctct-3′ 5′-gacaggtagctggcaagcac-3′ 55 44–84 12
7 5′-tcctctttatcctcctttct-3′ 5′-cacccaatcctctatcacta-3′ 50 25–65 6
8 5′-caggtgtttaatggctgaac-3′ 5′-taaattttaccaataagagc-3′ 48 37–77 6
9 5′-tccacttagcgattcgtcta-3′ 5′-tggaaaaaggcagatgggtg-3′ 53 28–68 6
10 5′-aatatatctgtgtttttcct-3′ 5′-ctctggtatgttctactaaa-3′ 53 15–59 4
11a 5′-accctgtgcttctcatgcgt-3′ 5′-GCTGGCTGGTGAAGAAGGAT-3′ 53 38–78 6
11b 5′-GCTGTCCGCTCTGTGTCAAT-3′ 5′-ACATCGGAGGTATCTGGAGG-3′ 53 44–84 8
a Exon sequences are shown as uppercase letters; and intron sequences are shown as lowercase letters. A 40-bp GC-clamp (5′-
GGGGCGGGGGCGGCGGGACGGGGCGCGGGGGCGGGGGCG-3′) was attached to the 5′-end of the reverse primers.
Table A2
Sequencing Conditions
EXON
SEQUENCING PRIMER
OPTIMAL
ANNEALING
TEMPERATURE
(C)Sense Antisense
1 GTGGTGGGGAGCGGGCTTCT GATCCTGGCCCTGGCGGC 55
2 TTACCTGCCTGCAGAGAAATGC GCTGGGCTGTTTCTGTGGTG 55
3 AAGTGTGACAAATCAACCGTTG TTGAGAGACACACATGTCAATG 50
4 AACGTTTCTCAGGTTGCTAAGCT TTCATAACTACTTCGAAAGAACTA 52
5 TAATAGCCCCTCACAAATAC ATTTTTGCCAGCACCGTATC 50
6 AGCAGGAGTCTGTTTTTATTTCAC ATGAGAAGCTGATTCACACTAGA 52
7 TTTCCTTCCATTTCTTTCTTCC GAAATCACCCAATCCTCTATCA 52
8 CAGGTGTTTAATGGCTGAAC AAATAAATTTTACCAATAAGAG 49
9 GGGGTACTACAGACCGTCAG GATGGAAAAAGGCAGATGG 53
10 AAAAAGGAAAATAAAATATATC TTCTCAGAGGATTACTCTCT 46
11 TGTGGAGTTGAAAACATCAGAAGAG CGGGGTCCACCGGCGGGGG 58
Table A3
Primers for FECH Expression Study
Primer Type Primer Sequencea
Selection 5′-ACACTCCGCTATCGCTCCGCGACTGGGTCATGGCT-3′
Mutagenic:
I71K 5′-AGGAAGCCGAAAACTGGAAAATTAATGCTAAACAT-3′
S151P 5′-GAATTGCCCCCCAACACAGCCCCTCAC-3′
Y191H 5′-AGGGCTATTGCTTTCACACAGCATCCACAGTACAG-3′
P192T 5′-AGGGCTATTGCTTTCACACAGTATACACAGTACAG-3′
T283I 5′-GAGGTAAGCGCCATTGTCCAAAAAGTCATG-3′
M288K 5′-AAAGTCAAGGAAAGGCTGGAGTACTGCAACCCCTA-3′
P334L 5′-GTTCTGATAGCATTTACCAGTGACCATATTGAAAC-3′
delCTT1248 5′-TGCAGGGAGACTAAATCCT*TCACCAGCCAGCA-3′
a Mutated bases that either abolish the unique BsaAI restriction site or intro-
duce the desired mutations are underlined; and the asterisk (*) indicates the
position of the deletion.
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